Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock By Investing.com

Jon Faiz Kayyem, a director at Inhibrx Biosciences, Inc. (), recently acquired shares of the company’s common stock. On September 16, 2026, Kayyem purchased 5,000 shares for a total value of $500,000.

The acquisition was made at a price of $100 per share. The stock currently trades at $104.73, near Kayyem’s purchase price, though it has declined 6% over the past week. Despite recent volatility, INBX shares have surged 295% over the past year, according to InvestingPro data. Following this transaction, Kayyem’s indirect beneficial ownership includes shares held by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust, the Jon Faiz Kayyem Revocable Trust, the Paige Gates-Kayyem Revocable Trust, and custodial accounts for his minor children. The insider purchase comes as InvestingPro analysis indicates the stock is currently overvalued relative to its Fair Value. For investors seeking comprehensive valuation insights, InvestingPro offers access to 11 additional ProTips and detailed financial metrics for INBX.

In other recent news, Inhibrx Biosciences announced promising results from the Phase 2 portion of the HexAgon-HN trial, evaluating its drug INBRX-106 in combination with Keytruda for head and neck cancer. The combination therapy achieved a confirmed overall response rate of 48.3% and a median progression-free survival of 9.6 months, surpassing Keytruda alone, which showed a 26.5% response rate and 4.9 months of progression-free survival. Following these results, H.C. Wainwright reiterated its Buy rating for Inhibrx with a price target of $245.00. Stifel also maintained its Buy rating, setting a price target of $325.00, citing attractive prospects ahead of upcoming data disclosures. Meanwhile, Citizens reiterated a Market Perform rating based on a revenue and earnings multiple analysis. Additionally, Inhibrx expanded its credit facility with Oxford Finance LLC to $500 million, securing $100 million immediately and the option to draw an additional $225 million. These developments highlight significant advancements and financial maneuvers for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.